
How proteomic insights and biobanks are powering the future of precision medicine
Yan Zhang, President of proteomic sciences at Thermo Fisher Scientific, writes about developments in precision medicine and how biobanks are key to realising this therapy area’s full impact. While a one-size-fits-all approach to patient care is still common in many areas, there have been meaningful strides toward more personalised healthcare in recent years. Targeted therapies have reshaped outcomes for many cancers. Companion diagnostics have moved from concept… Read More















